This is a preview of subscription content, log in via an institution to check access.
Reference
Hakim A, et al. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs. JAMA: the Journal of the American Medical Association : 13 Nov 2017. Available from: URL: http://doi.org/10.1001/jama.2017.16481
Rights and permissions
About this article
Cite this article
Costs increase after approval of unapproved marketed drugs. PharmacoEcon Outcomes News 792, 2 (2017). https://doi.org/10.1007/s40274-017-4525-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4525-3